Skip to main content
Journal ArticleOPEN ACCESS

Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy

Molecular Therapy Methods and Clinical Development (2020) 17 922-935
DOI: 10.1016/j.omtm.2020.04.010
34Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Anti-resorptive therapies targeting osteoclasts have proven effective in preserving bone mass, but these therapeutic agents lead to numerous side effects. The authors show that silencing cathepsin K in osteoclasts by delivering an artificial miRNA via bone-homing AAV9 can counteract bone loss in mouse models of postmenopausal and senile osteoporosis.

Author supplied keywords

Cite

CITATION STYLE

APA

Yang, Y. S., Xie, J., Chaugule, S., Wang, D., Kim, J. M., Kim, J. H., … Shim, J. H. (2020). Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy. Molecular Therapy Methods and Clinical Development, 17, 922–935. https://doi.org/10.1016/j.omtm.2020.04.010

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free